hiv-1 c4-v3 polyvalent peptide vaccine
Vaccineexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00001060)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- hiv-1 c4-v3 polyvalent peptide vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00005779 | Phase 1 | Jun 3, 2000 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000886 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00001060 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID), Pfizer |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 3 | 1 | 1999 |
| Pfizer | For profit | 1 | 0 | 1 | 1999 |
2 organizations
Page 1 / 1